Dahlberg J, Carlqvist J, Örtoft A, Hammarstedt L, Aula E, Hellström M et al.
BJS 2026; 113: znag076.
Of the 195 included patients, Bethesda IV-VI cytology was more frequent in the selective cytology group (26 versus 13 per cent, P=0.039), and the proportion of patients undergoing cytology fell from 83 to 71 per cent, with similar malignancy rates (8 versus 5 per cent). Among patients with at least one EU-TIRADS 3 or higher nodule, cytology was omitted in 7 per cent of the selective group and none of the non-selective group.
Comment: EU-TIRADS improved diagnostic yield without missing cancers.
Comment by Jeongyoon (Jenny) Moon, MD
.png)
.jpg){kind=logo}
